OncoMatch

OncoMatch/Clinical Trials/NCT06555068

A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients

Is NCT06555068 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments for advanced unresectable or metastatic breast cancer.

Phase 1/2RecruitingJiangsu HengRui Medicine Co., Ltd.NCT06555068Data as of Sep 2026Location: China

Treatment: HRS-6209 in Combination with Fulvestrant · HRS-6209 in Combination with HRS-1358 · HRS-6209 in Combination with Letrozole · HRS-6209 in Combination with HRS-8080 · HRS-6209 in Combination with HRS-9813 and Letrozole · HRS-6209 in Combination with HRS-9813 and HRS-8080The study is being conducted to evaluate the safety, PK and efficacy of HRS-6209 in Combination with Fulvestrant, Letrozole, HRS-8080, or HRS-1358 for advanced unresectable or metastatic breast cancer

Check if I qualify

Extracted eligibility criteria

Treatments studied

Endocrine / hormonal

HRS-6209 in Combination with FulvestrantHRS-6209 in Combination with LetrozoleHRS-6209 in Combination with HRS-9813 and Letrozole

Other

HRS-6209 in Combination with HRS-1358HRS-6209 in Combination with HRS-8080HRS-6209 in Combination with HRS-9813 and HRS-8080

Cancer type

Breast Carcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≤ 75
Female only

Prior therapy

Cannot have received: fulvestrant (fulvestrant)

Exception: for cohort of HRS-6209 in combination with fulvestrant (efficacy expansion stage)

Previous use of fulvestrant for cohort of HRS-6209 in combination with fulvestrant (efficacy expansion stage)

Lab requirements

Blood counts

Adequate organ and marrow function as defined by the protocol

Kidney function

Adequate organ and marrow function as defined by the protocol

Liver function

Adequate organ and marrow function as defined by the protocol

Adequate organ and marrow function as defined by the protocol

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06555068 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior fulvestrant disqualifies patients from enrollment.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Is this trial open to male patients?

No. This trial enrolls female patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify